Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zai Lab (ZLAB) Other financing activities (2020 - 2025)

Historic Other financing activities for Zai Lab (ZLAB) over the last 6 years, with Q1 2025 value amounting to $854000.0.

  • Zai Lab's Other financing activities rose 2200.0% to $854000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 10528.57%. This contributed to the annual value of $1.3 million for FY2024, which is N/A changed from last year.
  • Per Zai Lab's latest filing, its Other financing activities stood at $854000.0 for Q1 2025, which was up 2200.0% from $583000.0 recorded in Q4 2024.
  • In the past 5 years, Zai Lab's Other financing activities registered a high of $973000.0 during Q1 2021, and its lowest value of $1000.0 during Q4 2021.
  • Moreover, its 3-year median value for Other financing activities was $583000.0 (2024), whereas its average is $567714.3.
  • Data for Zai Lab's Other financing activities shows a peak YoY increase of 3383.77% (in 2021) and a maximum YoY decrease of 9997.56% (in 2021) over the last 5 years.
  • Zai Lab's Other financing activities (Quarter) stood at $1000.0 in 2021, then surged by 58200.0% to $583000.0 in 2024, then soared by 46.48% to $854000.0 in 2025.
  • Its Other financing activities stands at $854000.0 for Q1 2025, versus $583000.0 for Q4 2024 and $700000.0 for Q1 2024.